150 related articles for article (PubMed ID: 37957523)
1. The Impact of Biosimilar Use on Total Cost of Care and Provider Financial Performance in the Medicare Oncology Care Model: A Population-Based Simulation Study.
Yang J; Chaudhry BI; Yue AT; Roth JA; Kelton JM; Shelbaya A; Tran L; Li M
Adv Ther; 2024 Jan; 41(1):349-363. PubMed ID: 37957523
[TBL] [Abstract][Full Text] [Related]
2. Biosimilar Use Among 38 ASCO PracticeNET Practices, 2019-2021.
Bourbeau B; Lyman GH; Lei XJ; Jones L; Rosenthal J; Kozlik MM; Oettel KR; Tinger A; Page R
JCO Oncol Pract; 2023 Jul; 19(7):516-522. PubMed ID: 37084324
[TBL] [Abstract][Full Text] [Related]
3. Association of Participation in the Oncology Care Model With Medicare Payments, Utilization, Care Delivery, and Quality Outcomes.
Keating NL; Jhatakia S; Brooks GA; Tripp AS; Cintina I; Landrum MB; Zheng Q; Christian TJ; Glass R; Hsu VD; Kummet CM; Woodman S; Simon C; Hassol A;
JAMA; 2021 Nov; 326(18):1829-1839. PubMed ID: 34751709
[TBL] [Abstract][Full Text] [Related]
4. Greater uptake, an alternative reimbursement methodology needed to realize cost-saving potential of oncology biosimilars in the United States.
Yang J; Carioto J; Pyenson B; Smith R; Jacobson N; Pittinger S; Shelbaya A
J Manag Care Spec Pharm; 2021 Dec; 27(12):1642-1651. PubMed ID: 34677089
[No Abstract] [Full Text] [Related]
5. Hematologic Malignancy Episodes Exceed Target Price in Oncology Care Model.
Nguyen J; Maio V; Walsh K; Handley N; Patel S; Keith SW; Csik VP
Am J Med Qual; 2023 Jul-Aug 01; 38(4):174-180. PubMed ID: 37314239
[TBL] [Abstract][Full Text] [Related]
6. The Economics of Provider Payment Reform: Are Accountable Care Organizations the Answer?
Feldman R
J Health Polit Policy Law; 2015 Aug; 40(4):745-60. PubMed ID: 26124297
[TBL] [Abstract][Full Text] [Related]
7. Physician, Practice, and Patient Characteristics Associated With Biosimilar Use in Medicare Recipients.
Dean EB; Johnson P; Bond AM
JAMA Netw Open; 2021 Jan; 4(1):e2034776. PubMed ID: 33502485
[TBL] [Abstract][Full Text] [Related]
8. Association of Oncologist Participation in Medicare's Oncology Care Model With Patient Receipt of Novel Cancer Therapies.
Manz CR; Tramontano AC; Uno H; Parikh RB; Bekelman JE; Schrag D
JAMA Netw Open; 2022 Sep; 5(9):e2234161. PubMed ID: 36173630
[TBL] [Abstract][Full Text] [Related]
9. A Clinical Review of Biosimilars Approved in Oncology.
Ngo D; Chen J
Ann Pharmacother; 2021 Mar; 55(3):362-377. PubMed ID: 32715722
[TBL] [Abstract][Full Text] [Related]
10. Assessing Medicare's Approach To Covering New Drugs In Bundled Payments For Oncology.
Muldoon LD; Pelizzari PM; Lang KA; Vandigo J; Pyenson BS
Health Aff (Millwood); 2018 May; 37(5):743-750. PubMed ID: 29733731
[TBL] [Abstract][Full Text] [Related]
11. Medicare's Bundled Payment Initiatives for Hospital-Initiated Episodes: Evidence and Evolution.
Yee CA; Pizer SD; Frakt A
Milbank Q; 2020 Sep; 98(3):908-974. PubMed ID: 32820837
[TBL] [Abstract][Full Text] [Related]
12. Implementing and Optimizing Biosimilar Use at Mayo Clinic.
Jensen CJ; Tichy EM; Lempke MB; Ewald AM; Erickson SJ; Holm MR; Soefje SA
Mayo Clin Proc; 2022 Jun; 97(6):1086-1093. PubMed ID: 35337661
[TBL] [Abstract][Full Text] [Related]
13. Modeling Episode-Based Payments for Cancer Using Commercial Claims Data.
Polson M; Lord T; Evangelatos T; Kangethe A; Speicher LC; Barrientos S; Zacker C
J Manag Care Spec Pharm; 2019 Feb; 25(2):235-245. PubMed ID: 30698092
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis.
Yang J; Yu S; Yang Z; Yan Y; Chen Y; Zeng H; Ma F; Shi Y; Shi Y; Zhang Z; Sun F
BioDrugs; 2019 Aug; 33(4):373-389. PubMed ID: 31161461
[TBL] [Abstract][Full Text] [Related]
15. The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions.
Bennett CL; Nagai S; Bennett AC; Hoque S; Nabhan C; Schoen MW; Hrushesky WJ; Luminari S; Ray P; Yarnold PR; Witherspoon B; Riente J; Bobolts L; Brusk J; Tombleson R; Knopf K; Fishman M; Yang YT; Carson KR; Djulbegovic B; Restaino J; Armitage JO; Sartor OA
Oncologist; 2021 Aug; 26(8):e1418-e1426. PubMed ID: 33586299
[TBL] [Abstract][Full Text] [Related]
16. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
[TBL] [Abstract][Full Text] [Related]
17. Biosimilars: Implications for Clinical Practice.
Rifkin RM; Peck SR
J Oncol Pract; 2017 Sep; 13(9_suppl):24s-31s. PubMed ID: 28898593
[TBL] [Abstract][Full Text] [Related]
18. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
Cuellar S; McBride A; Medina P
Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
[TBL] [Abstract][Full Text] [Related]
19. The Biosimilar Paradox: How Anti-Vascular Endothelial Growth Factor Biosimilars Could Increase Patient and Overall Health Care Costs.
Zhang C; Friedman S; Mruthyunjaya P; Parikh R
Ophthalmology; 2023 Sep; 130(9):966-972. PubMed ID: 37116720
[TBL] [Abstract][Full Text] [Related]
20. Biosimilars in oncology: Effects on economy and therapeutic innovations.
Hübel K; Kron F; Lux MP
Eur J Cancer; 2020 Nov; 139():10-19. PubMed ID: 32950935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
